Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by nobody – 2019-04-05 08:37  – Posting: # 20124
Views: 1,121

» The fact that it is also a royal waste of money is of course only secondary.

Full-blown development mode. Accept it. Tell the sponsor you can't do the trial, if you are not qualified for PD-endpoint testing.

Kindest regards, nobody

Complete thread:

Activity
 Admin contact
20,134 posts in 4,245 threads, 1,386 registered users;
online 14 (0 registered, 14 guests [including 8 identified bots]).
Forum time (Europe/Vienna): 07:27 CET

A Camel is a Horse designed by committee.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5